Urine-Based Test Improves on PSA for Detecting Prostate Cancer
A new urine-based test improved prostate cancer detection—including detecting more aggressive forms of prostate cancer—compared to traditional models based on prostate-specific antigen (PSA) levels. The results were published by Tomlins et al in European Urology.
The test, developed at the University of Michigan Comprehensive Cancer Center, is called Mi-Prostate Score, or MiPS. It combines PSA with two markers for prostate cancer, T2:ERG and PCA3, both of which can be detected through a urine sample. The test has been available clinically since September 2013.
“Around 50% of men who undergo a prostate biopsy will not have cancer. We need better ways to manage elevated PSA and determine who really needs to have a biopsy. MiPS gives men and their doctors better information to help make those decisions,” said lead study author Scott A. Tomlins, MD, PhD, Assistant Professor of Pathology and Urology at the University of Michigan Medical School.
Study Results
The study looked at a total of 1,977 men who were undergoing prostate biopsy because of elevated PSA levels. Using urine samples, the researchers conducted MiPS testing and compared results to various combinations of PSA, PCA3, T2:ERG, and other PSA-based risk calculators. They assessed how well the individual biomarkers and combinations of biomarkers predicted the likelihood of cancer and the likelihood of high-risk cancer.
The test reports individual risk estimates for prostate cancer and high-grade cancer. Each patient’s personal threshold for choosing to undergo biopsy may vary, so there is no single cutoff for a “positive” result.
However, using one MiPS cutoff score to decide whether to biopsy patients would reduce the number of biopsies by one-third, while delaying the diagnosis of only about 1% of high-risk prostate cancers.
“MiPS gives men a more individualized risk assessment for prostate cancer, so that men concerned about their serum PSA levels can have a more informed conversation with their doctor about next steps in their care,” Dr. Tomlins said. A cost/benefit analysis of MiPS is being conducted.
PCA3 is approved by the U.S. Food and Drug Administration for prostate cancer risk assessment in men with a previous negative biopsy. Most of the men involved in this study were undergoing initial biopsy, suggesting MiPS can be useful earlier in the process.
Arul Chinnaiyan, MD, PhD, is the corresponding author for the European Urology article.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
